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Abstract
Background Cyclooxygenase isoenzyme-2 (COX-2) and vascular endothelial growth factor (VEGF) contribute to angio-
genesis and are overexpressed in various malignancies. The aim of the study was to evaluate expression, prognostic value and
correlation between COX-2 and VEGF expression in esophageal adenocarcinoma (EAC).
Methods Surgical specimens of 154 patients with EAC were used to construct a tissue micro array (TMA). TMA sections
were immunohistochemically stained for COX-2 and VEGF and scored on intensity of staining.
Results Estimated 5-year cancer specific survival was 37%. High COX-2 and VEGF expression was observed in 39 (26.5%)
and in 77 (53.8%) tumors, respectively. Both markers were associated with poor cancer specific survival (p0.022 and
p0.004, respectively, log rank). No significant correlation was found between VEGF and COX-2 expression (r0063;
p0.455). In multivariate analysis, high COX-2 expression (HR 1.65; 95% CI 1.04–2.61; p0.034) was associated with
overall survival. In patients with T3 tumors, COX-2 expression was an independent prognostic factor for cancer specific
survival (HR 1.81 95% CI 1.10–2.95; p0.019).
Conclusions This is the first study that evaluated the prognostic value and correlation of COX-2 and VEGF expression in a
large and homogenous population of patients with EAC. No correlation between COX-2 and VEGF expression was found.
Both markers were expressed in EAC and were associated with poor prognosis. The findings support the use of COX-2 and
VEGF inhibitors in future clinical studies.
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Introduction
Worldwide, esophageal cancer is the 7th leading cause of
cancer death.
1 Advancements in diagnostics, surgical tech-
niques, and the application of neoadjuvant chemotherapy
have improved survival rates. Studies report 5-year survival
rates of up to 40% for patients with resectable disease.
2–4
Further therapeutic improvements are warranted and the
focus is now turning to targeted therapy. This has led to an
increasing interest in the prognostic and therapeutic value of
biological tumor markers that are known to play a key role
in carcinogenesis and progression. Markers which can be
selectively blocked with pharmaceuticals are of particular
interest.
5–7 Two of these biomarkers, cyclooxygenase-2
(COX-2) and vascular endothelial growth factor (VEGF),
may play a significant role in esophageal adenocarcinoma
(EAC).
COX-2 is the rate-limiting enzyme involved in the con-
version of arachidon acid to eisosanoids such as prostaglan-
din (PG), prostacyclin and tromboxanes. Its expression is
induced by several stimuli including growth factors, inflam-
mation, and cytokines. Overexpression of COX-2 is
reported in many human malignancies such as colon,
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9 pancreas,
10 lung,
11 breast carcinoma,
12 and also in
esophageal cancer.
13,14
The VEGF gene family belongs to the platelet-derived
growth factor (PDGF) gene and encodes for VEGF-A, B, C,
D, E, and placenta growth factor (PIGF). VEGF-A, referred
to as VEGF, is the most potent endothelial cell specific
mitogen that induces angiogenesis, which is critical to both
tumor growth and systemic spreading of tumor cells.
15 High
VEGF expression is reported in several malignancies, in-
cluding esophageal cancer.
13,16–19
A relationship between COX-2 and VEGF has been de-
scribed earlier.
20,21 COX-2 generated PGs contributed to an-
giogenesis through the induction of VEGF. Moreover, it was
demonstrated that COX-2 inhibition (e.g., with the use of
diclofenac, rofecoxib, or celecoxib) resulted in both COX-2
and VEGF protein downregulation. These findings suggest
that COX-2 and VEGF expression are interlinked.
22,23
The role of COX-2 and VEGF and their interaction in
EAC is yet unclear. The aim of this study was to evaluate
expression and prognostic significance of COX-2 and
VEGF in adenocarcinoma of the esophagus. Furthermore,
the correlation between COX-2 and VEGF protein expres-
sion in EAC was evaluated.
Materials and Methods
Study Population
All patients who underwent esophagectomy for cancer be-
tween August 1988 and November 2009 at the University
Medical Center Utrecht were collected in a database.
Patients with histologically proven EAC were included.
Patients with esophageal squamous cell carcinoma (ESCC),
neoadjuvant treatment, pathological T4 disease, distant me-
tastases, tumor positive resection margins (R1) according to
the College of American Pathologists (CAP) criteria,
24 and
patients who died in-hospital or within 30 days from oper-
ation were excluded from the study.
All tumor resection specimens were reviewed by an
experienced pathologist (FJWtK). Tumors were staged
according to the TNM staging system (7th edition).
25 A
follow-up study was performed in which patients were
followed up until death or up to July 2011. Follow-up data
were collected with the use of chart examination, general
practitioners archives, and the Dutch Cancer Registry.
Primary outcome was the percentage of COX-2 and
VEGF expression. Secondary outcomes were the correlation
between COX-2 and VEGF expression as well as cancer
specific survival (CSS; defined as the time between surgery
and death due to cancer) and overall survival (OS; defined
as the time between surgery and death). The study was
performed in accordance with the local ethical guidelines
concerning informed consent using patient’s material after
surgical resection.
TMA Construction
Formalin-fixed, paraffin-embedded tumor blocks were used
for construction of a tissue micro array (TMA) as described
earlier by Boone et al.
13 Briefly, for each tumor specimen,
three representative regions were marked on the pathologi-
cal hematoxylin and eosin-stained slide. These regions, re-
ferred to as tumor cores, were punched out and placed into
the TMA paraffin block.
Immunohistochemistry
From the TMA, 4-μm sectioned slides were deparaffinized
in xylene (15 min) and dehydrated in serial ethanol dilutions
(15 min). Between all steps, tumor slides were rinsed with
Tris–HCl buffered saline pH 7.4 (TBS). The endogenous
peroxide activity was blocked by hydrogen peroxidase
(0.3%) methanol solution for 20 min. Antigen retrieval
was achieved by boiling the slides for 10 min in 0.01 mol/
L sodium citrate (pH 6.0). Then TMA slides were incubated
during 60 min in blocking solution (contents: 0.1 mol/L
Tris–HCl pH 7.4; 1 mol/L MgCl2; Tween-20; 10%BSA;
Goat serum and H2O) to block unspecific binding sites.
Subsequently, TMA slides were incubated with COX-2
monoclonal antibody (Cayman Chemical, Catalog#160112,
Clone CX229, dilution 1:100), overnight at 4°C. The next
day slides were rinsed with TBST (Tris–HCl buffered saline
pH 7.4 with Tween-20) and post-antibody blocking solution
(not diluted) was added for 15 min. Subsequently, slides
were incubated with polyclonal Goat-anti-Mouse/Rabbit/
Rat IgG (not diluted) during 30 min. Peroxidase staining
was visualized with 3-amino-9-ethylcarbazole solution and
slides were counter stained with hematoxylin (10 s).
For VEGF staining, tumor slides were deparaffinized in
xylene (15 min) and dehydrated in serial ethanol dilutions
(15 min).Between all steps,slideswererinsedwith phosphate
buffered saline pH7.4. The endogenous peroxide activitywas
blocked by hydrogen peroxide (3%) for 15 min. Antigen
retrieval was achieved by boiling the slides for 20 min in
sodium citrate (pH 6.0). After a cooling off period (20 min),
the slides were incubated with polyclonal VEGF165 antibody
(R&DSystems,Catalog#AF293NA,dilution1:50)for60min
at room temperature. Subsequently, TMA slides were incu-
bated with biotinylated secondary Rabbit-anti-Goat antibody
(1:50) for 30 min. Slides were treated with Strep Avidin–
Biotin complex for 30 min and peroxidase staining was visu-
alized using 3,3′-diaminobenzide for 10 min. The sections
were counterstained with hematoxylin (10 s).
For positive controls, colon and stomach carcinoma
(known to express high COX-2 protein) were included and
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Non-cancerous esophageal squamous cell epithelia were
used for internal control. Negative controls were achieved
by omitting the primary antibody.
Immunohistochemical Scoring
Immunohistochemical scoring was performed by FJWtK.
Cores were considered lost if less than 10% of the tissue
contained tumor (i.e., sampling error), less than 10% of
tissue was present (i.e., absent core), or when two out of
three cores were lost. The scoring of VEGF and COX-2
expression was based on the intensity of staining, which
ranged from 1 (no staining), 1 (weak), 2 (moderate), and 3
(strong staining). The lowest observed staining score for
COX-2 was 1. At least one tumor core had to have a score
of 3 to be considered as high COX-2 staining. The highest
scoring intensity observed in VEGF stained cores was 2. For
VEGF, the median score of the sum of the two highest cores
was calculated and used as a cutoff value. Tumors which
scored <1 were defined as low VEGF expression and tumors
which scored ≥ 1 as high VEGF staining.
Statistical Analysis
Association between clinical parameters and COX-2 and
VEGF staining were evaluated using cross tabulation (Pear-
son’s chi-square test). Survival rates were estimated by
using the Kaplan–Meier function (log rank test) to compare
the OS and CSS among patients with high versus low COX-
2 and VEGF expression. Correlation between COX-2 and
VEGF expression (dichotomous values) was evaluated us-
ing the Pearson’s correlation.
The following parameters were evaluated in univariate
analysis: T-stage (T1 or T2 vs. T3), lymph node metastases
(no vs. yes), differentiation grade (good and moderate vs.
poor), COX-2 (low vs. high), lymph node ratio (≤25% vs.
>25%), vasoinvasion (no vs. yes), perineural growth (no vs.
yes), VEGF (low vs. high), median age (<64 vs. ≥64 years),
gender, and perinodal extension (no vs. yes). Variables that
were significant in univariate analysis were included in
multivariate analysis (Cox proportional hazards regression
analysis). A p value of <.050 was considered statistically
significant. All analyses were performed using standard
statistical software (SPSS version 15.0; SPSS Inc., Chicago,
Illinois).
Results
Between 1988 and 2009, 290 patients underwent esophage-
al resection for EAC at the Department of Surgery of the
University Medical Centre Utrecht. Patients with tumor
positive resection margins (R1; n026), with T4 disease
(n07), patients who were pretreated (n049), and patients
whose clinical and/or pathological data were incomplete or
missing (n054) were excluded.
In a total of 154 patients, the female to male ratio was
1:4.5 with a median age of 64.0 years (range, 33.8–81.3).
Lymph node metastases were observed in 104 (67.5%)
patients of which 62 (59.6%) patients had perinodal exten-
sion (i.e., extra capsular location of tumor cells). A lymph
node ratio (i.e., the number of positive nodes divided by the
total number of resected nodes) of >25%
24 was observed in
48 (31.2%) patients.
Follow-up was complete in 144 (93.5%) patients with a
median follow-up of 26.4 months (range 2.7–260.3). Esti-
mated 5-year CSS was 37% (median CSS 30.4 months). All
patient and tumor characteristics are summarized in Table 1.
Table 1 Baseline char-
acteristics (n0154)
LNN lymph nodes
aData are n (%), unless
noted otherwise
bTumors were staged
according to the TNM
classification (anatomi-
cal stage groups, 7th
edition)
cIn 4 cases resection
specimen did not con-
tain lymph nodes. Medi-
an number of resected
lymph nodes was 13
(range 0–70)
dAs a proportion of
patients with lymph node
involvement (n0104)
n (%)
a
Gender
Male 126 (81.8)
Female 28 (18.2)
Age (years)
Median (range) 64.0 (33.8–81.3)
Type of resection
Transthoracic (open) 24 (15.6)
Transthoracic
(scopic)
24 (15.6)
Transhiatal (open) 105 (68.2)
Unknown 1 (0.6)
Tumor stage
b
I AB 25 (16.2)
II AB 24 (15.6)
III AB 69 (44.8)
III C 32 (20.8)
Unknown 4 (2.6)
Tumor extend (T stage)
T1 17 (11.0)
T2 35 (22.7)
T3 102 (66.2)
LNN involvement
Yes 104 (67.5)
No 46 (29.9)
Not present
c 4 (2.6)
LNN ratio>25%
Yes 48 (31.2)
No 102 (66.2)
Unknown
c 4 (2.6)
Perinodal extension
d
Yes 62 (59.6)
No 42 (40.4)
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Tumor cores of 147 (95.5%) patients were assessable for
COX-2 scoring. Overall COX-2 staining was seen in all
tumor cores (100%). Cytoplasmic COX-2 staining was high
in 39 (26.5%) tumors and low in 108 (73.5%) tumors
(Fig. 1a, b). COX-2 staining was positively associated with
lymph node metastases (p0.015, Table 2). Median CSS was
39.5 months in patients with low COX-2 expression (95%
CI 20.00–58.93) versus 21.0 months (95% CI 17.96–24.00)
in patients with high COX-2 expression (p0.022; log rank,
Fig. 2). High COX-2 expression was significantly and in-
versely associated with CSS (HR 1.70; 95% CI 1.07–2.69;
p0.023, Table 4). COX-2 expression was not associated
with recurrence of disease (p0.173, Table 2)
VEGF Expression
VEGF evaluation was assessable in tumor cores of 143
(92.9%) patients. Overall staining was seen in 90 (62.9%)
tumors. High cytoplasmic expression was seen in 77
(53.8%) and low staining in 66 (46.2%) of patients (Fig. 1c,
d). VEGF expression positively correlated with tumor stage
(p0.000), presence of lymph node metastases (p0.032) and a
lymph node ratio of >25% (p0.001, Table 3). In patients with
lymph node metastases, VEGF was significantly associated
with perinodal nodal extension (p0.024, data not shown).
Patients with high VEGF expression more frequently devel-
oped recurrence of disease (p0.004, Table 3). Patients with
low VEGF expression had a median CSS of 59.5 months
(95% CI 0.00–153.03), whereas patients with high VEGF
expression had a median CSS of 21.6 months (95% CI
16.18–27.02; p0.004; log rank, Fig. 3). High VEGF expres-
sion was significantly associated with poor CSS (HR 1.90;
95% CI 1.22–2.96; p0.005, Table 4).
Correlation between COX-2 and VEGF
Tumor cores of 143 (92.9%) patients were assessable for
combined evaluation of VEGF and COX-2 staining. There
was no significant correlation between VEGF and COX-2
expression (r0.063; p0.455).
Multivariate Analysis
In multivariate analysis, high COX-2 expression was not
associated with poor CSS (HR 1.55; 95% CI 0.95–2.53;
p0.081, Table 4). For OS, high COX-2 expression was
an independent prognostic factor (HR 1.65; 95% CI
1.04–2.61; p0.034, Table 5). VEGF expression was
not independently associated with CSS (HR 0.88; 95%
Fig. 1 Representative
examples of COX-2 and VEGF
staining. a Tumor core showing
strong (3+) cytoplasmic and
granular COX-2 staining. Stro-
mal tumor cells did not or only
slightly stain positive for COX-
2. Original magnification
(×200). b Magnification (×400)
of tumor core shown in a. c
Tumor core showing moderate
cytoplasmic VEGF staining (2
+). Original magnification
(×200). d Tumor cells showing
weak cytoplasmic VEGF stain-
ing (1+). Original magnification
(×200)
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95% CI 0.67–1.64; p0.848, Table 5).
In the subset of patients with advanced disease (i.e., T3
tumors), COX-2 was an independent prognostic marker for
CSS (HR 1.81; 95% CI 1.10–2.95; p0.019, Table 6) as well
as for OS (HR 1.90; 95% CI 1.18–3.05; p0.008, data not
shown).
Discussion
This is the first study that evaluated the prognostic value and
interaction of COX-2 and VEGF expression in a large and
homogenous population of patients with EAC. Patients who
received neo-adjuvant treatment or patients with T4 disease,
distant metastases at time of operation, and tumor positive
resection margins were excluded.
The Prognostic Value of COX-2 and VEGF Overexpression
The results showed high COX-2 and VEGF expression in
39 (26.5%) and in 77 (53.8%) of patients. Both were sig-
nificantly associated with poor CSS (p0.022 and p0.004,
respectively, log rank). In addition, COX-2 was indepen-
dently associated with poor OS. In patients with advanced
disease (T3), COX-2 was also an independent prognostic
marker for CSS. This suggests that COX-2 is particularly of
prognostic significance for patients with advanced disease.
Other studies have also identified COX-2 expression as
an independent prognostic factor in EAC
14,26,27 and in
ESCC.
28 Some authors have reported an independent prog-
nostic significance of VEGF overexpression in ESCC,
29–31
whereas other studies could not find any association be-
tween VEGF expression and survival in EAC
32 and
ESCC.
33–35 In EAC, only one study has showed the inde-
pendent prognostic value of VEGF overexpression.
18
Some important limitations of these studies must be
mentioned. Buskens et al., Takatori et al., Saad et al., and
Table 2 Correlation of COX-2 expression and clinical and patholog-
ical parameters
Total (n) COX-2 expression p value
b
Low (%) High (%)
Total
a 147 73.5 26.5 –
Gender
Male 121 76.0 24.0 .129
Female 26 61.5 38.5
Median age
<64 years 72 75.0 25.0 .680
≥64 years 75 72.0 28.0
Pathological data
T-stage
T1 or T2 46 82.6 17.4 .090
T3 101 69.3 30.7
Tumor differentiation
G1 or G2 55 72.7 27.3 1.000
G3 88 72.7 27.3
Vasoinvasion
Yes 69 75.4 24.6 .625
No 78 71.8 28.2
Perineural growth
Yes 43 65.1 34.9 .149
No 103 76.7 23.3
LNN metastases
Yes 102 68.6 31.4 .015
No 42 88.1 11.9
LNN ratio
≤25% 96 78.1 21.9 .138
>25% 48 66.7 33.3
Follow-up data
Recurrence and/or metastases
Yes 88 69.3 30.7 .173
No 50 80.0 20.0
Locoregional recurrence
Yes
c 31 74.2 25.8 .541
No 50 80.0 20.0
Distant metastases
Yes
c 75 68.0 32.0 .140
No 50 80.0 20.0
LNN lymph nodes
aTumor cores from 147 patients were assessable for COX-2 scoring
(147 of 154, 95.5%)
bPearson Chi-square test
cA proportion of patients (n018) experienced both locoregional and
distant metastases
Fig. 2 Cancer specific survival according to high and low COX-2
staining. Log rank test was used to compare differences between
survival curves
960 J Gastrointest Surg (2012) 16:956–966Ogata et al. included patients who had distant metastases at
time of resection, which was seen in 19% (28/145), 33%
(75/228), 40% (30/75), and in 24% (22/92) of cases,
respectively.
14,18,28,31 In addition, the series of Buskens et
al. included 33 of 145 (23%) patients with a positive resec-
tion margin.
14 Patients with distant metastases and positive
resection margins have poor prognosis irrespective of COX-
2 expression. The inclusion of such cases greatly affects the
survival rate of the studied population, making it difficult to
interpret the correlation between protein expression and
prognosis. Furthermore, many of these studies analyzed
OS instead of CSS.
14,26,27
Correlation between COX-2 and VEGF Expression
COX-2 and VEGF both play an important role in carcino-
genesis, tumor progression, and angiogenesis. In the studied
cohort, we did not observe a correlation between VEGF and
COX-2 expression (r0.063; p0.455). Other studies with
varying population size, patient selection, and methodology
reported otherwise and suggest that the two markers are
interlinked.
23,36,37
Vallböhmer et al. (n075) and von Rahden et al. (n0123)
evaluated the quantity of VEGF and COX-2 messenger
RNA in EAC using quantitative reverse transcription poly-
merase chain reaction (qRT-PCR). Both authors reported a
significant correlation between COX-2 and VEGF (r0.460,
p<.001 and r0.764, p<.001, respectively).
23,36 However,
Vallböhmer et al. investigated a mixed population (16
patients with ESCC, 15 with Barrett’s esophagus, and 44
with EAC) and found that COX-2 and VEGF expressions
were only correlated when the overall study population was
analyzed.
36
In another study of 40 patients with ESCC, a signif-
icant correlation between high COX-2 (65.4%) and
VEGF (50%) expression (p<.005) was reported using immu-
nohistochemistry (IHC).
37 The study included patients who
received neoadjuvant therapy before surgery. Pathological
Table 3 Correlation of VEGF expression and clinical and pathological
parameters
Total (n) VEGF expression p value
b
Low (%) High (%)
Total
a 143 46.2 53.8 –
Gender
Male 117 44.4 55.6 .384
Female 26 53.8 46.2
Median age
<64 years 71 49.3 50.7 .454
≥64 years 72 43.1 56.9
T-stage
T1 or T2 44 72.7 27.3 .000
T3 99 34.3 65.7
Tumor differentiation
G1 or G2 52 53.8 46.2 .090
G3 87 39.1 60.9
Vasoinvasion
Yes 68 38.2 61.8 .071
No 75 53.3 46.7
Perineural growth
Yes 41 43.9 56.1 .695
No 101 47.5 52.5
LNN metastases
Yes 100 40.0 60.0 .032
No 40 60.0 40.0
LNN ratio
≤25% 93 55.9 44.1 .001
>25% 47 25.5 74.5
Follow-up data
Recurrence and/or metastases
Yes 87 35.6 64.4 .004
No 47 61.7 38.3
Locoregional recurrence
Yes
c 30 26.7 73.3 .003
No 47 61.7 38.3
Distant metastases
Yes
c 75 37.3 62.7 .009
No 47 61.7 38.3
LNN lymph nodes
aTumor cores from 143 patients were assessable for VEGF scoring
(143 of 154: 92.9%)
bPearson chi-square test
cA proportion of patients (n018) experienced both locoregional and
distant metastases
Fig. 3 Cancer specific survival according to high and low VEGF
staining. Log rank test was used to compare differences between
survival curves
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was seen in 35% of patients. The evaluation of tumor specific
protein expression in specimens without visible tumor cells is
questionable. However, these specimens were considered as
negative staining for both COX-2 and VEGF. This increased
the proportion of VEGF and COX-2 co-expression (i.e., neg-
ative staining).
Relationship of COX-2 and VEGF Expression and Clinical
and Pathological Parameters
Analysis of (linear) relationships between COX-2 expression
and prognostic parameters showed a significant correlation
between high COX-2 expression and the presence of lymph
node metastases. This is consistent with previous
Table 4 Univariate and multivariate analysis of associations between histopathologic parameters and cancer specific survival (CSS)
Median CSS in months Unadjusted HR (95% CI) p value Adjusted HR (95% CI)
a p value
Negative Positive Univariate Multivariate
Perinodal extension
c 26.9 20.7 1.864 (1.160–2.995) .010
Gender (male/female) 32.2 26.7 1.050 (0.592–1.860) .868
Median age (<64/≥64 years) 24.5 37.6 1.001 (0.657–1.525) .998
T stage (T1,T2/T3)
b 22.9 10.282 (4.441–23.807) .000 3.833 (1.404–10.468) .009
Positive lymph nodes
b 23.2 6.595 (3.166–13.740) .000 2.338 (0.979–5.587) .056
G grade (G1,G2/G3)
d 127.9 21.2 2.952 (1.809–4.817) .000 2.103 (1.214–3.644) .008
LNN ratio (≤0.25/>25) 64.3 18.5 3.832 (2.194–5.213) .000 1.595 (0.943–2.698) .082
COX-2 (low/high) 39.4 21.0 1.698 (1.074–2.685) .023 1.546 (0.947–2.525) .081
Vasoinvasion
b 21.6 3.283 (2.107–5.116) .000 1.538 (0.901–2.623) .114
Perineural growth 49.4 21.2 2.532 (1.633–3.927) .000 1.142 (0.705–1.851) .589
VEGF (low/high) 59.5 21.6 1.897 (1.216–2.959) .005 0.877 (0.544–1.415) .591
LNN lymph nodes, CI confidence interval
aMultivariate analysis was carried out with variables proven significant in univariate analysis
bMedian survival was not determined, since expected cumulative survival within the study period did not reach 50%
cAs a proportion of patients with positive lymph nodes (n0100). Perinodal extension was not included in multivariate analysis
dG grade indicates tumor differentiation
Table 5 Univariate and multivariate analysis of associations between histopathologic parameters and overall survival (OS)
Median OS in months Unadjusted HR (95% CI) p value Adjusted HR (95% CI)
a p value
Negative Positive Univariate Multivariate
Perinodal extension
b 26.7 19.2 1.736 (1.108–2.722) .016
Gender (male/female) 24.0 29.0 1.120 (0.674–1.860) .661
Median age (<64/≥64 Y) 24.4 27.4 1.319 (0.899–1.934) .157
T stage (T1,T2/T3) 196.1 21.2 5.537 (3.148–9.736) .000 2.974 (1.390–6.364) .005
G grade (G1,G2/G3)
c 64.3 19.5 2.864 (1.846–4.443) .000 2.218 (1.342–3.665) .002
COX-2 (low/high) 29.1 19.5 1.732 (1.138–2.636) .010 1.645 (1.037–2.607) .034
Vasoinvasion 61.6 21.2 2.635 (1.771–3.922) .000 1.458 (0.897–2.367) .128
Positive lymph nodes 193.1 22.9 3.585 (2.130–6.034) .000 1.393 (0.730–2.657) .314
LNN ratio (≤0.25/>25) 48.9 18.3 2.592 (1.735–3.873) .000 1.355 (0.827–2.221) .228
Perineural growth 39.4 21.0 2.333 (1.536–3.543) .000 1.139 (0.714–1.815) .585
VEGF (low/high) 41.3 21.0 1.945 (1.295–2.920) .001 1.045 (0.667–1.636) .848
LNN lymph nodes, CI confidence interval
aMultivariate analysis was carried out with variables proven significant in univariate analysis
bAs a proportion of patients with positive lymph nodes (n0100). Perinodal extension was not included in multivariate analysis
cG grade indicates tumor differentiation
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27,37,38 High VEGF expression was significantly cor-
related with depth of tumor invasion (T-stage), presence of
lymph node metastases, lymph node ratio, and perinodal
growth.Inaddition,expressionwasassociatedwithrecurrence
of disease. This is also consistent with previous studies which
describe a correlation between VEGF and T-stage,
18,29,35,39,40
lymph node metastases,
18,39–43 and recurrence of disease.
18,29
COX-2 and VEGF expression were both associated with
lymphatic tumor metastases. A possible explanation might be
found in the involvement of HIF-1α, which is an important
transcription factor regulating transcription of genes that are
involved in metastatic spreading of disease. COX-2 and
VEGF are target genes of HIF-1α and are both responsible
for vasodilation, increased vessel permeability, and tumor cell
invasion. We hypothesize that COX-2 and VEGF both lead to
vasodilatation of lymphatic vessels leading to increased mi-
crovascular permeability. The leaky state of microvessels
causes extravasation of tissue metalloproteinase, which is also
inducedbyCOX-2andVEGF.
44,45Thiscausesdegradationof
the extracellular matrix, further facilitating invasion of cancer
cells into the lymphatic vessels. Furthermore, VEGF-induced
metalloproteinases may lead to degradation of basement
membraneand therefore to higherT-stage (i.e.,depthoftumor
invasion). Again, this is hypothetical and requires investiga-
tion in future studying.
Evaluation of COX-2 and VEGF Expression
Using Immunohistochemistry (IHC)
Reported rates of high VEGF and COX-2 protein expression
in esophageal cancer vary widely from 25% to 91% for COX-
2
13,14,46 and 24% to 80% for VEGF expression.
13,18,30,35,40,42
This variation is mostly due to differences in patient selection
(e.g., inclusion of patients with both ESCC and EAC, with
distant metastases, or positive resection margins) and meth-
odology (e.g., the use of different cutoff values, reagents, or
scoring methods).
It might be argued that evaluation of messenger RNA
expression with qRT-PCR and Northern blot techniques
provides a more objective analysis of COX-2 and VEGF
expression. However, IHC is the most frequently used and
most reliable method today for analyzing protein expression
from formalin-fixed and paraffin-embedded material. IHC is
still the gold standard to evaluate tumor marker expression
for diagnostic purposes. Moreover, a major advantage of
IHC above other techniques is that it enables precise
location of the (increased) signal within the tumor cell.
With techniques that evaluate messenger RNA expres-
sion the histology of the tumor is no longer available.
These techniques may overestimate COX-2 and VEGF
expression because non-cancerous tissues such as in-
flammatory cells and vascular endothelial cells (that also
express high levels COX-2 and VEGF) are included in
the sample.
Targeted Therapies with COX-2 and VEGF Inhibitors
The results showed that COX-2 and VEGF expression were
both associated with poor survival. Therefore, specific inhi-
bition of these pathways may affect prognosis. To date,
several trials have been conducted with VEGF inhibitors
such as monoclonal antibody bevacizumab or tyrosine
Table 6 Univariate and multivariate analysis of associations between histopathologic parameters and cancer specific survival (CSS) in T3 tumors
(n0100)
Median CSS in months Unadjusted HR (95% CI) p value Adjusted HR (95% CI)
a p value
Negative Positive Univariate Multivariate
Gender (male/female) 23.2 16.4 1.461 (0.818–2.608) .200
Perineural growth 23.2 21.2 1.387 (0.887–2.169) .151
Perinodal extension
b 24.0 20.7 1.261 (0.775–2.052) .350
VEGF (low/high) 23.9 21.0 1.056 (0.665–1.677) .819
Median age (<64/≥64 years) 22.1 24.0 1.012 (0.653–1.567) .959
G grade (G1, G2/G3)
c 37.6 19.1 2.335 (1.373–3.971) .002 2.017 (1.159–3.511) .013
COX-2 (low/high) 24.4 19.1 1.769 (1.099–2.847) .019 1.805 (1.103–2.954) .019
Positive lymph nodes 41.3 22.9 2.200 (1.005–4.816) .048 1.822 (0.789–4.209) .160
Vasoinvasion 26.9 20.7 2.020 (1.278–3.195) .003 1.640 (0.963–2.791) .068
LNN ratio (≤0.25/>25) 26.7 18.5 2.226 (1.420–3.488) .000 1.453 (0.859–2.458) .163
LNN lymph nodes, CI confidence interval
aMultivariate analysis was carried out with variables proven significant in univariate analysis
bAs a proportion of patients with positive lymph nodes (n088)
cG grade indicates tumor differentiation
J Gastrointest Surg (2012) 16:956–966 963kinase inhibitors like sorafenib.
47–49 Other trials included
COX-2 specific inhibitors such as celecoxib.
22,50,51
Two phase I–IItrials,applyingchemoradiotherapy(cisplat-
in,fluorouracil)addedwithcelecoxib,reportclinicalcomplete
response 7 of 13 patients (54%) and pathological complete
response in 5 of 22 patients (22%), respectively.
50,51 Further-
more, Tuynman et al. reported significant COX-2 downregu-
lation in patients who underwent neoadjuvant celecoxib
treatment (p<.010).
22 Although concerns exist about long-
term usage of COX-2 inhibitors with regard to its potential
cardiovascular risk,
52 in all studies celecoxib was accompa-
nied with acceptable toxicities without cardiovascular events.
A phase II study combining chemotherapy (irinotecan and
cisplatin) with bevacizumab treatment in 34 patients resulted
inanoverall responserate(i.e.,completeand partialresponse)
of 65% (complete pathologic response in 6%).
47 Another
phase II study, which combined doxetaxel and cisplatin with
sorafenib, yielded 41% partial response (complete response in
0%).
48 A phase II study with doxetaxel, cisplatin, and fluoro-
uracil added with bevacizumab (n039) showed a response
rate of 67% (complete response in 5%).
49 These results sup-
port the use of VEGF and COX-2 inhibitors in future studies.
Combining the inhibitors could possibly show synergistic
effects, ultimately benefitting patients’ prognosis.
Future Perspectives
At present, all patients receive neoadjuvant treatment.
Therefore, it is not possible to validate the prognostic value
of COX-2 and VEGF expression in a prospective cohort.
However, it would be of great value to prospectively eval-
uate COX-2 and VEGF expression in pre-treatment biop-
sies. Using this method, correlation between COX-2 and
VEGF expression and response to neoadjuvant treatment
can be evaluated. When patients are not expected to benefit
from adjuvant therapy, surgery could be rescheduled accord-
ingly to prevent further progression of disease.
In conclusion, the results show high COX-2 in a quarter
of EAC patients and high VEGF expression in over half of
EAC patients. Both markers were associated with poor
prognosis. Moreover, COX-2 was an independent prognos-
tic marker for survival. Although a relationship between
COX-2 and VEGF expression could not be identified, the
findings support the use of COX-2 and VEGF inhibitors in
future clinical studies.
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